NCT03310463View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

May 25, 2018

Study Completion Date

May 29, 2018

Conditions
Acinetobacter Baumannii Infection
Interventions
DRUG

ETX2514SUL

Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion

Trial Locations (3)

33136

University of Miami, Division of Clinical Pharmacology, Miami

55404

Davita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

Sponsors
All Listed Sponsors
lead

Entasis Therapeutics

INDUSTRY

NCT03310463 - Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects | Biotech Hunter | Biotech Hunter